Biomerica (NASDAQ:BMRA) and Nobel Biocare (OTCMKTS:NBHGF) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, risk, institutional ownership, valuation, dividends and earnings.

Volatility & Risk

Biomerica has a beta of -0.13, suggesting that its share price is 113% less volatile than the S&P 500. Comparatively, Nobel Biocare has a beta of -0.25, suggesting that its share price is 125% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent recommendations for Biomerica and Nobel Biocare, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Biomerica 0 0 1 0 3.00
Nobel Biocare 0 0 0 0 N/A

Biomerica presently has a consensus price target of $7.50, indicating a potential upside of 177.78%.

Profitability

This table compares Biomerica and Nobel Biocare’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Biomerica -31.75% -41.73% -34.79%
Nobel Biocare N/A N/A N/A

Institutional and Insider Ownership

1.8% of Biomerica shares are held by institutional investors. 26.8% of Biomerica shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Biomerica and Nobel Biocare’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Biomerica $5.56 million 4.39 -$1.46 million ($0.17) -15.88
Nobel Biocare N/A N/A N/A N/A N/A

Nobel Biocare has lower revenue, but higher earnings than Biomerica.

Summary

Biomerica beats Nobel Biocare on 5 of the 8 factors compared between the two stocks.

Biomerica Company Profile

Biomerica, Inc., together with its subsidiaries, develops, manufactures, and markets medical diagnostic products for the early detection and monitoring of chronic diseases and medical conditions. The company's diagnostic test kits are used to analyze blood, urine, or fecal samples from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific hormones, antibodies, antigens, or other substances, which exist in the human body in extremely small concentrations. It primarily focuses on products for gastrointestinal diseases, food intolerances, diabetes, and various esoteric tests. The company offers its products to hospital and clinical laboratories, medical research institutions, medical schools, pharmaceutical companies, chain drugstores, wholesalers, and physicians' offices, as well as to distributors. It operates in Europe, the United States, Asia, South America, the Middle East, and internationally. Biomerica, Inc. was founded in 1971 and is headquartered in Irvine, California.

Receive News & Ratings for Biomerica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biomerica and related companies with MarketBeat.com's FREE daily email newsletter.